Shuttle Pharma files provisional patent for PSMA-targeted PARP inhibitor conjugates for prostate cancer therapy

Shuttle Pharmaceuticals Holdings, Inc.

Filed provisional patent for PSMA-targeted PARP inhibitor conjugates, co-invented by Dr. Alan Kozikowski who contributed to Pylarify and Pluvicto.
Theranostic molecule aims to preferentially target prostate cancer cells, enhancing radiation and chemotherapy effects.
Global PSMA PET Imaging Market was $1.5B in 2022, expected to reach $2.0B by 2030; Pluvicto market predicted at $2B.
Shuttle Diagnostics subsidiary focuses on PSMA-B ligand and PC-Rad test for predicting RT outcomes in localized prostate cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.